Pulse 探索 nav.journalClub 辩论趋势研究者期刊

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

首页探索 nav.journalClub 趋势

⌘+K

Transcatheter Aortic Valve Replacement in a Failed Homograft | Synapse

March 22, 2026JACC Case Reports0 citationsOpen Access

Transcatheter Aortic Valve Replacement in a Failed Homograft

View Full Paper

MRMaximilian ReisingerUniversity of Vermont Medical Center JVJay VanceUniversity of Vermont TGThomas GillilandUniversity of Vermont Medical Center

Key Points

To explore the effectiveness of transcatheter aortic valve replacement in patients with failed homografts.
Discussion of TAVR devices designed specifically for aortic regurgitation (AR) treatment.
Analysis of the implications of commercial approval for TAVR devices.
TAVR is likely to become the preferred treatment option for patients with failed homografts after commercial approval.

Abstract

Dedicated TAVR devices for AR will likely become the preferred treatment for failed homografts after commercial approval.

问 AI

Like

Bookmark

Share

View Full Paper

问 AI

Like

Bookmark

Share

View Full Paper

Cite This Study

Reisinger et al. (Sun,) studied this question.

synapsesocial.com/papers/69bf393dc7b3c90b18b43b4f https://doi.org/https://doi.org/10.1016/j.jaccas.2026.107516